Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789882 | 1.00 | FFAR1 (0.49) | FFAR1FFAR4GPR84NFKB1FAAH | |
| SCHEMBL9685329 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL1712736 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL11748318 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL910534 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL1712990 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL9685588 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL9334962 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL2397949 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR | |
| SCHEMBL9200158 | 0.98 | FFAR1 (0.52) | FFAR1FFAR4GPR84FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332011-A1 | TOTAL SYNTHESIS OF PROSTAGLANDIN J NATURAL PRODUCTS BY TEREORETENTIVE METATHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332011-A1 | TOTAL SYNTHESIS OF PROSTAGLANDIN J NATURAL PRODUCTS BY TEREORETENTIVE METATHESIS | PTGES, PTGES2, PTGIS | FFAR1 327/4885FFAR4 460/4885GPR84 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.